High-Throughput Screening of Low Molecular Weight NS3-NS4A Protease Inhibitors Using a Fluorescence Resonance Energy Transfer Substrate
暂无分享,去创建一个
Yasuaki Shimizu | Kenji Sudo | K. Shimotohno | Kunitada Shimotohno | K. Sudo | Y. Shimizu | K. Yamaji | N. Kojima | Kayo Yamaji | Kouich Kawamura | Tomoko Nishijima | Naoko Kojima | Kazuhiko Aibe | K. Aibe | Kouichi Kawamura | Tomoko Nishijima
[1] K. Shimotohno,et al. Bacterial expression and analysis of cleavage activity of HCV serine proteinase using recombinant and synthetic substrate. , 1995, Biochemical and biophysical research communications.
[2] K. Shimotohno,et al. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. , 1997, Biochemical and biophysical research communications.
[3] R. Francesco,et al. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins , 1994, Journal of virology.
[4] M. Houghton,et al. Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease , 1991, Hepatology.
[5] A. Urbani,et al. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. , 1996, Analytical biochemistry.
[6] A. Urbani,et al. Activity of purified hepatitis C virus protease NS3 on peptide substrates , 1996, Journal of virology.
[7] N. Kato,et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus , 1993, Journal of virology.
[8] H. Okayama,et al. Structure and organization of the hepatitis C virus genome isolated from human carriers , 1991, Journal of virology.
[9] K. Shimotohno,et al. Novel Hepatitis C virus Protease Inhibitors: 2,4,6-Trihydroxy,3-Nitro-Benzamide Derivatives , 1997 .
[10] C. Rice,et al. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites , 1993, Journal of virology.
[11] C. Decicco,et al. Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. , 2003, Bioorganic & medicinal chemistry letters.
[12] X. Forns,et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. , 2004, Gastroenterology.
[13] Y. Masuho,et al. Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease , 1996, Journal of virology.
[14] G. Fields,et al. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). , 1994, The Journal of biological chemistry.
[15] B. Dunn,et al. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. , 1995, Analytical biochemistry.
[16] K. Shimotohno,et al. A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. , 1999, Journal of virological methods.
[17] K. Shimotohno,et al. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. , 1996, Antiviral research.
[18] J. Pichardo,et al. Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum. , 1999, Bioorganic & medicinal chemistry letters.
[19] P. Barr,et al. Genetic organization and diversity of the hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[20] G Murphy,et al. A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.
[21] K. Shimotohno,et al. Non‐peptide inhibitors of HCV serine proteinase , 1998, FEBS letters.
[22] Todd C Appleby,et al. Hepatitis C Virus Therapies: Current Treatments, Targets and Future Perspectives , 2003, Antiviral chemistry & chemotherapy.
[23] B. Douty,et al. Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[24] Steven R. LaPlante,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.
[25] K. Shimotohno,et al. Expression of a hepatitis C virus NS3 protease-NS4A fusion protein in Escherichia coli. , 1998, Biochemical and biophysical research communications.
[26] Gary T. Wang,et al. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. , 1990, Science.
[27] C. Rice,et al. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[28] B. Handa,et al. Design and Synthesis of a Quenched Fluorogenic Peptide Substrate for Human Cytomegalovirus Proteinase , 1995 .
[29] Martin Poirier,et al. Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position. , 2004, Journal of medicinal chemistry.
[30] Robert B. Johnson,et al. Development of a Continuous Fluorescence Assay for Rhinovirus 14 3C Protease Using Synthetic Peptides , 1997 .
[31] R. Bartenschlager,et al. Kinetic and structural analyses of hepatitis C virus polyprotein processing , 1994, Journal of virology.
[32] J. Pawlotsky. The nature of interferon-alpha resistance in hepatitis C virus infection. , 2003, Current opinion in infectious diseases.
[33] T. Sugimura,et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[34] Giovanni Migliaccio,et al. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. , 2003, Antiviral research.